Loading clinical trials...
Loading clinical trials...
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-64304500 in Patients With Alopecia Areata
Conditions
Interventions
JNJ-64304500
Placebo
Locations
22
United States
Forcare Clinical Research, Inc.
Tampa, Florida, United States
Indiana Clinical Trial Center
Plainfield, Indiana, United States
Dermatology Specialists
Louisville, Kentucky, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Oregon Dermatology and Research Center
Portland, Oregon, United States
Start Date
March 24, 2021
Primary Completion Date
June 2, 2022
Completion Date
July 20, 2022
Last Updated
May 4, 2021
NCT06826196
NCT06562270
NCT07133308
NCT06327581
NCT07023302
NCT07152119
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions